Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/cid/ciaa935 http://scihub22266oqcxt.onion/10.1093/cid/ciaa935 32628748!7454474!32628748     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Infect+Dis 2021 ; 72 (4): 710-715 Nephropedia Template TP {{tp|p=32628748|t=2021. Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development |pdf=|usr=}}{{32628748}} gab.com Text Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development JO: Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32628748 #FOAvip Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss 3 potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and improving understanding of pathogenesis and the human immune response. We outline the limitations of HCTs and find that HCTs are likely to be most useful for vaccine candidates currently in preclinical stages of development. We conclude that, while currently limited in their application, there are scenarios in which HCTs would be extremely beneficial. Therefore, the option of conducting HCTs to accelerate SARS-CoV-2 vaccine development should be preserved. As HCTs require many months of preparation, we recommend an immediate effort to (1) establish guidelines for HCTs for COVID-19; (2) take the first steps toward HCTs, including preparing challenge virus and making preliminary logistical arrangements; and (3) commit to periodically re-evaluating the utility of HCTs. Twit Text FOAVip Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development ????Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32628748 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32628748 #FOAvip English Wikipedia <ref>{{Cite pmid|32628748}}</ref> Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development #MMPMID32628748 Nguyen LC; Bakerlee CW; McKelvey TG; Rose SM; Norman AJ; Joseph N; Manheim D; McLaren MR; Jiang S; Barnes CF; Kinniment M; Foster D; Darton TC; Morrison J Clin Infect Dis 2021[Feb]; 72 (4): 710-715 PMID32628748show ga Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss 3 potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and improving understanding of pathogenesis and the human immune response. We outline the limitations of HCTs and find that HCTs are likely to be most useful for vaccine candidates currently in preclinical stages of development. We conclude that, while currently limited in their application, there are scenarios in which HCTs would be extremely beneficial. Therefore, the option of conducting HCTs to accelerate SARS-CoV-2 vaccine development should be preserved. As HCTs require many months of preparation, we recommend an immediate effort to (1) establish guidelines for HCTs for COVID-19; (2) take the first steps toward HCTs, including preparing challenge virus and making preliminary logistical arrangements; and (3) commit to periodically re-evaluating the utility of HCTs. |*COVID-19[MESH] |*SARS-CoV-2[MESH] |COVID-19 Vaccines[MESH] |Clinical Trials as Topic[MESH] |Humans[MESH]Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-C(epmc).pdf DeepDyve Pubget Overpricing